SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A minor change in the total revenue was seen in the September 2023 quarter. The total revenue for the quarter stood at Rs. 22334.16 millions against Rs. 22082.12 millions during year ago period.The Net Profit of the company registered a slight decline of -28.55% to Rs. 3023.54  millions from Rs. 4231.51 millions.The Operating Profit of the company witnessed a decrease to 5170.68 millions from 6991.58 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 22334.16 22082.12 1.14 43778.00 41201.42 6.25 82206.62 81415.81 0.97
Other Income 735.78 3167.28 -76.77 1229.39 6632.46 -81.46 9859.39 6146.28 60.41
PBIDT 5170.68 6991.58 -26.04 10514.25 14795.00 -28.93 24587.06 23028.49 6.77
Interest 581.87 524.69 10.90 1201.21 922.32 30.24 2068.16 2360.41 -12.38
PBDT 4392.12 6466.89 -32.08 8800.06 13872.68 -36.57 17560.22 24971.41 -29.68
Depreciation 498.46 461.66 7.97 985.98 911.99 8.11 1841.48 1596.95 15.31
PBT 3893.66 6005.23 -35.16 7814.08 12960.69 -39.71 15718.74 23374.46 -32.75
TAX 870.12 1773.72 -50.94 2073.98 3803.37 -45.47 3631.05 3396.57 6.90
Deferred Tax 777.97 889.89 -12.58 1596.18 1815.97 -12.10 -238.26 -714.21 -66.64
PAT 3023.54 4231.51 -28.55 5740.10 9157.32 -37.32 12087.69 19977.89 -39.49
Equity 282.17 282.17 0.00 282.17 282.17 0.00 282.17 282.17 0.00
PBIDTM(%) 23.15 31.66 -26.88 24.02 35.91 -33.12 29.91 28.29 5.74

Glenmark Pharma Share Price

2364.35 -6.70 (-0.28%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×